Myocardial tissue oxygen consumption pathways

"Myocardial tissue oxygen consumption pathways" encompass the physiology and cellular metabolism whereby the heart muscle utilizes oxygen exclusively via *aerobic pathways* (oxidative phosphorylation within mitochondria). The heart has limited anaerobic capacity and nearly all its ATP production is dependent on continuous oxygen delivery through coronary circulation. Increased heart rate, contractility, and wall tension drive higher oxygen demand, which is matched by regulatory mechanisms including changes in coronary blood flow, metabolic feedback (local release of vasodilators such as adenosine during hypoxia or ischemia), and neurohumoral control (sympathetic stimulation via β- and α-adrenoceptors). Dysregulation or mismatches between oxygen supply and consumption are central to the pathology of ischemia, infarction, and heart failure. While enzymes, receptors, and channels are involved in these regulatory pathways (ATPase, cytochrome oxidase, β-adrenoceptors, adenosine receptors, K_ATP channels), the concept as stated refers broadly to these integrated processes—not a specific discrete therapeutic target.

Other names

Myocardial oxygen consumptionCardiac oxygen utilizationCardiac metabolic pathwaysOxidative phosphorylation in myocardiumMyocardial aerobic metabolism

Drugs affect myocardial tissue oxygen consumption pathways by various means: they can reduce myocardial oxygen demand (e.g., beta blockers, Ca channel blockers), increase oxygen supply (e.g., vasodilators, nitrates), improve coronary blood flow (e.g., vasodilatory drugs), or enhance oxygen extraction or efficiency (e.g., metabolic modulators).